On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.
The SMAD-specific E3 ubiquitin protein ligase 2 (SMURF2) has emerged as a critical regulator in cancer biology, modulating the stability of Hypoxia-Inducible Factor 1-alpha (HIF1α)…
This Viewpoint discusses whether psychiatric disorders are diseases of the brain.
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic…
Dyslipidaemia in patients with diabetes contributes to the risk of atherosclerotic cardiovascular disease. We aimed to identify a dyslipidemic profile associated with both dysglycemia and…
Kennedy reportedly said the right things when confronted over past positions and statements that have made some Republicans uneasy.
Based on the IMpower133 trial, atezolizumab plus carboplatin and etoposide (+CE) is approved as first-line treatment for ES-SCLC. The J-TAIL-2 study evaluated atezolizumab +CE in…
Mother of girl who died in 2013 reveals figures on Today programme that are welcomed by national medical director
The idea that hearts carry feelings and memories is nothing new.
